L'International Antiviral Society ajoute Trogarzo(MC) à ses directives de traitement

       

Theratechnologies annonce que Trogarzo injection a été ajouté à la plus récente version des directives de traitement émises par l'International Antiviral Society-USA Panel. Les directives viennent d'être publiées dans la dernière édition du Journal of the American Medical Association. 

Les nouvelles directives de l'IAS stipulent que "Ibalizumab, an anti-CD4 monoclonal antibody that inhibits HIV cell entry via CD4 binding, is active against CCR5- and C-X-C chemokine receptor 4 (CXCR4)?tropic HIV isolates and may be useful as a fully active agent for patients with multiclass-resistant virus (evidence rating BII). Almost 50% of adults with virologic failure from multidrug-resistant HIV achieved undetectable HIV RNA levels at 24 weeks after receipt of biweekly intravenous ibalizumab (800 mg) with at least 1 other active drug."